MRVI Maravai LifeSciences Holdings

Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100

Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences.

Dr. Kate Broderick joined the Company in 2022 as Senior Vice President of Research and Development (R&D) at TriLink Biotechnologies, part of Maravai LifeSciences. Dr. Broderick was promoted to lead Maravai’s Science and Innovation Office as Chief Innovation Officer, developing and executing an overarching innovation roadmap and strategy and partnering closely with R&D teams in each corporate operating division to support and drive new ideas. Dr. Broderick has a 20-year track record of success in the biotechnology industry and is renowned for her expertise in vaccine and DNA technology. Notably, Dr. Broderick led an R&D team at Inovio who designed a DNA-based vaccine for COVID-19, and the TriLink Biotechnologies team’s CleanCap® reagent has been pivotal for mRNA technologies deployed in many global and commercial manufacturing programs, including the Pfizer-BioNTech COVID-19 mRNA vaccine Comirnaty®.

“I am honored to be included among this year’s influential biopharma leaders on the 2023 PharmaVoice 100 list,” said Dr. Broderick. “Working alongside the incredible team at Maravai, I have had the opportunity to foster innovation and help realize the extraordinary potential of nucleic acid technology to improve human health. I feel very fortunate to guide Maravai’s impressive innovation engine, which enables the miracles of science during an exciting time in the biotechnology industry.”

Dr. Kate Broderick’s profile as a member of the 2023 PharmaVoice 100 can be found .

About PharmaVoice 100

Since 2005, the PharmaVoice 100 — and Red Jacket honorees — have become one of the publication’s most anticipated features. PharmaVoice developed the only awards program in the industry to recognize individuals of all ages and sectors of the life sciences — from academia to nonprofits, Big Pharma, startups, tech companies, service providers and more. The PharmaVoice 100 contains a diverse mix of professionals across a range of disciplines — from the clinic to the C-suite — who are making meaningful contributions in their fields and striving to improve outcomes for patients.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit .



Contact Information:

Media Contact: 
Sara Michelmore 
MacDougall Advisors
  
 

Investor Contact: 
Deb Hart 
Maravai LifeSciences 
  
  
EN
19/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE

Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Maravai LifeSciences Reports Second Quarter 2025 Financial Results Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted EBITDA and Positive Free Cash Flow expected by second half 2026 SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life s...

 PRESS RELEASE

Maravai LifeSciences To Host Earnings Conference Call on Monday, Augus...

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025 SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 267-6316 or (203) 518-9783 and reference Maravai LifeSciences, Conf...

 PRESS RELEASE

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Offic...

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  “We thank Kevin for his commitment to Maravai and his...

 PRESS RELEASE

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer a...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execut...

 PRESS RELEASE

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch